{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:11:15Z","timestamp":1790179875099,"version":"4.1.0"},"reference-count":65,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,10,3]]},"DOI":"10.1080\/13543776.2025.2548925","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T02:46:00Z","timestamp":1755657960000},"page":"1039-1050","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the patent portfolio for helicase-primase inhibitor ABI-5366 of Assembly Biosciences Inc"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-2774","authenticated-orcid":false,"given":"Christian","family":"Gege","sequence":"first","affiliation":[{"name":"Innovative Molecules GmbH","place":["M\u00fcnchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Kleymann","sequence":"additional","affiliation":[{"name":"Innovative Molecules GmbH","place":["M\u00fcnchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"Herpes simplex virus World Health Organization. 2024 Dec 11 [cited 2025 Feb 12]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/herpes-simplex-virus#:~:text=Key%20facts main%20cause%20of%20genital%20herpes"},{"key":"e_1_3_5_4_1","volume-title":"Fields Virology: DNA Viruses","author":"Howley PM","year":"2021","unstructured":"Howley PM, Knipe DM, Damania BA, et al. Fields Virology: DNA Viruses. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2021.","edition":"7"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.006"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-392"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.827663"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13948"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13081547"},{"key":"e_1_3_5_10_1","unstructured":"Maruho receives manufacturing and marketing approval for a partial change of the indication and dosage\/administration for anti-herpes virus agent \u201cAmenalief Tab. 200mg\u201d for the treatment of recurrent herpes simplex in Japan. [cited 2024 Apr 27]. Available from: www.maruho.co.jp\/english\/information\/20230224.html"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00668"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301150"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18189"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1241"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00183"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1358"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8668"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16027"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01732-22"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.899"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073220"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105190"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105733"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1138"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2113873"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202100177"},{"key":"e_1_3_5_27_1","unstructured":"Medshine Discovery Inc. Thiazole derivative and applications thereof. WO2018\/127207. 2018."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867323666160405112353"},{"key":"e_1_3_5_29_1","unstructured":"Gilead Sciences Inc. Solid forms of a HSV helicase primase inhibitor. WO2025\/104687. 2025."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2024.2403618"},{"key":"e_1_3_5_31_1","unstructured":"Assembly Biosciences Inc. Pharmaceutical compositions for herpes virus. WO2024\/047508. 2024."},{"key":"e_1_3_5_32_1","unstructured":"Assembly Biosciences Inc. Cyclic urea thiazolyl compounds for treatment of HSV. WO2024\/049760. 2024."},{"key":"e_1_3_5_33_1","unstructured":"Assembly Biosciences Inc. Oral pharmaceutical compositions. WO2024\/224304. 2024."},{"key":"e_1_3_5_34_1","unstructured":"Assembly Biosciences Inc. A crystalline form of 2-(3-(2 5\u2019-difluoro-[1 1\u2019-biphenyl]-4-yl)-2-oxotetrahydropyridin-1(2H)-yl)-4-methylthiazole-5-sulfonamide. WO2025\/046456. 2025."},{"key":"e_1_3_5_35_1","unstructured":"Assembly Biosciences Inc. A crystalline form of 2-(3-(2 5\u2019-difluoro-[1 1\u2019-biphenyl]-4-yl)-2-oxotetrahydropyridin-1(2H)-yl)-4-methylthiazole-5-sulfonamide. WO2025\/046457. 2025."},{"key":"e_1_3_5_36_1","volume-title":"Oral Presentation at the 47th Annual International Herpesvirus Workshop 2023","author":"Contreras H","year":"2023","unstructured":"Contreras H, Shen M, Schulze G, et al. Pre-clinical characterization of ABI-5366: a highly potent long-acting helicase-primase inhibitor for the treatment of high recurrence genital herpes. In: Oral Presentation at the 47th Annual International Herpesvirus Workshop 2023; Missoula, Montana; 2023 Jul 19 [cited 2023 Sep 27]. Available from: https:\/\/investor.assemblybio.com\/events-presentations"},{"key":"e_1_3_5_37_1","volume-title":"Poster Presentation at the 47th Annual International Herpesvirus Workshop 2023","author":"Contreras H","year":"2023","unstructured":"Contreras H, Shen M, Schulze G, et al. Pre-clinical characterization of ABI-5366: a highly potent long-acting helicase-primase inhibitor for the treatment of high recurrence genital herpes. In: Poster Presentation at the 47th Annual International Herpesvirus Workshop 2023; Missoula, Montana; 2023 Jul 15\u201319 [cited 2023 Sep 27]. Available from: https:\/\/investor.assemblybio.com\/\/events-presentations"},{"key":"e_1_3_5_38_1","volume-title":"Poster Presentation at the 48th Annual International Herpesvirus Workshop 2024","author":"Contreras H","year":"2024","unstructured":"Contreras H, Stray K, Azimova D, et al. The helicase-primase inhibitor ABI-5366 is a novel, potent, long-acting inhibitor for the treatment of recurrent genital herpes. In: Poster Presentation at the 48th Annual International Herpesvirus Workshop 2024; Portland, Oregon; 2024 Jul 13\u201317 [cited 2025 Feb 13]. Available from: https:\/\/investor.assemblybio.com\/events\/event-details\/48th-annual-international-herpesvirus-workshop-ihw"},{"key":"e_1_3_5_39_1","unstructured":"Assembly Biosciences corporate presentation. 2025 Mar [cited 2025 Mar 23]. Available from: https:\/\/investor.assemblybio.com\/static-files\/ba046960-33df-4458-8bb5-bfd9d6f90b62"},{"key":"e_1_3_5_40_1","unstructured":"Bayer AG. Thiazolyl urea derivatives and their utilization as antiviral agents. WO2000\/053591. 2000."},{"key":"e_1_3_5_41_1","unstructured":"Bayer AG. Thiazolyl amide derivatives. WO2001\/047904. 2001."},{"key":"e_1_3_5_42_1","unstructured":"Bayer AG. Indolinylamide derivatives. WO2000\/076966. 2000."},{"key":"e_1_3_5_43_1","unstructured":"Bayer AG. Inverse thiazolyl amide derivatives. WO2002\/012211. 2002."},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568012043354242"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02714"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02092"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.3c00210"},{"key":"e_1_3_5_48_1","unstructured":"Aicuris Anti-Infective Cures GmbH. N-[5-(aminosulfonyl)-4-methyl-1 3-thiazol-2-yl]-N-methyl-2-4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate methods of manufacture and uses thereof. WO2018\/096170. 2018."},{"key":"e_1_3_5_49_1","unstructured":"Aicuris Anti-Infective Cures GmbH. Ophthalmic formulation comprising N-[5-(aminosulfonyl)-4-methyl-1 3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide hemihydrate. WO2021\/191320. 2021."},{"key":"e_1_3_5_50_1","unstructured":"Assembly Biosciences Inc. A novel crystalline form of pritelivir. WO2024\/047506. 2024."},{"key":"e_1_3_5_51_1","unstructured":"Assembly Biosciences Inc. A novel crystalline form of pritelivir. WO2024\/047507. 2024."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9MD00233B"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00396-012-2848-y"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.115828"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2020.100052"},{"key":"e_1_3_5_56_1","volume-title":"Poster presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025","author":"Shen M","year":"2025","unstructured":"Shen M, Li C, Zong Z, et al. Preclinical profile of ABI-5366, a novel potent HSV helicase-primase inhibitor, with potential for weekly or monthly oral dosing for the treatment of recurrent genital herpes. In: Poster presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025; Vienna, Austria; 2025 Apr 11\u201315 [cited 2025 Jun 23]. Available from: https:\/\/investor.assemblybio.com\/static-files\/3595faee-cf09-4fbd-997c-48fec66a6e50"},{"key":"e_1_3_5_57_1","volume-title":"Poster presentation at the 48th Annual International Herpesvirus Workshop 2024;","author":"Cho A","year":"2024","unstructured":"Cho A, Nair V, May L, et al. Preclinical characterization of ABI-1179, a potent helicase primase inhibitor for the treatment of recurrent genital herpes. In: Poster presentation at the 48th Annual International Herpesvirus Workshop 2024; Portland, Oregon; 2024 Jul 13\u201317 [cited 2025 Apr 3]. Available from: https:\/\/investor.assemblybio.com\/static-files\/8a408cf9-818d-45fd-ae3e-a242a49e35d4"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01541"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2022.2105318"},{"key":"e_1_3_5_60_1","first-page":"11","volume-title":"Poster presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025;","author":"Gane EJ","year":"2025","unstructured":"Gane EJ, Schwabe, C, Wang, G, et al. The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: interim results from a phase 1a\/1b study in healthy participants. In: Poster presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025; Vienna, Austria; 2025 Apr; p. 11\u201315. [cited 2025 Jun 23]. Available from: https:\/\/investor.assemblybio.com\/static-files\/663d21da-2c91-4f5d-8733-233a0867eb69"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129761"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.3390\/v16071037"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060679"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54775"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl067"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz357"},{"key":"e_1_3_5_67_1","volume-title":"Innovative Molecules, oral presentation at the International Congress on Antiviral Research (ICAR) 2025;","author":"Blank A","year":"2025","unstructured":"Blank A, Bergamino M, Burhenne J, et al. First-in-human, single ascending dose, phase 1 trial to assess safety, tolerability, and pharmacokinetics of IM-250, a helicase-primase inhibitor against herpes simplex virus, in healthy volunteers. In: Innovative Molecules, oral presentation at the International Congress on Antiviral Research (ICAR) 2025; Las Vegas, Nevada; 2025 Mar 17\u201321."}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2548925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:30:36Z","timestamp":1759480236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2548925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,3]]}},"alternative-id":["10.1080\/13543776.2025.2548925"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2548925","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}